Recent Trends and Challenges in Meningitis Treatment: A Pharmacological Perspective

Meningitis is a serious medical condition in which the protective membranes covering the brain and spinal cord, called the meninges, become inflamed. It is commonly caused by bacterial, viral, or fungal infections, with bacterial meningitis being the most severe form. The disease progresses rapidly
and can cause fever, headache, neck stiffness, nausea, and confusion. If not treated promptly, it can lead to long-term complications such as hearing loss, seizures, brain damage, or death.
Treatment of meningitis is evolving due to challenges such as the blood-brain barrier (BBB), antimicrobial resistance (AMR), and long-term neurological effects in survivors. Relapse may occur when infection returns after initial treatment, often due to incomplete eradication of pathogens, resistant strains, or delayed therapy. To address these issues, healthcare is shifting toward faster, patient-centered strategies. Recent diagnostic advances have transformed meningitis management. Traditional cerebrospinal fluid (CSF) cultures, which take several days, are being replaced by rapid molecular tools such as multiplex
PCR, capable of detecting multiple pathogens within an hour, and CSF C-reactive protein (CRP) tests that provide results in just 30 minutes. Prevention has also improved with next-generation vaccines, including the pentavalent MenABCWY and the affordable Men5CV, offering broader protection and simpler immunization schedules. Emerging therapies like nanomedicine and pharmacogenomics aim to improve drug delivery across the BBB and support personalized treatment approaches. Furthermore, about one in five survivors of bacterial meningitis suffers permanent problems such as neurological damage or physical disabilities. Continued research, innovative therapies, and active pharmacist involvement are essential to enhance meningitis prevention, diagnosis, and treatment globally.